Abbott Laboratories ABT
Set alert
At close · Nov 2
After hours · Nov 2, 7:29 PM ET
- YTD
- -12.08%
- 1 year
- -10.89%
- Open
- 106.89
- Prev close
- 106.20
- Mkt cap
- 190.62B
- Vol
- 8.85M
- Avg vol
- 8.75M
- EPS
- 2.69
- P/E
- 40.95
- Div yield
- 2.37%
More statistics
- Low
- 106.40
- High
- 110.48
- Forward P/E
- 18.57
- Beta
- 0.54
- Short ratio
- 1.84
- Inst. own
- 81.92%
- Dividend
- 2.52
- Ex-div date
- Oct 14, 2026
- Earnings
- Jan 28, 2027
- 50-d avg
- 104.34
- 200-d avg
- 101.69
- 1y target
- 118.52
5Y chart
Events in this range
- Jan 13, 2022Dividend: 0.47
- Apr 13, 2022Dividend: 0.47
- Jul 14, 2022Dividend: 0.47
- Oct 13, 2022Dividend: 0.47
- Jan 12, 2023Dividend: 0.51
- Apr 13, 2023Dividend: 0.51
- Jul 13, 2023Dividend: 0.51
- Oct 12, 2023Dividend: 0.51
- Oct 13, 2023Dividend: 0.51
- Jan 11, 2024Dividend: 0.55
- Jan 12, 2024Dividend: 0.55
- Apr 12, 2024Dividend: 0.55
- Jul 15, 2024Dividend: 0.55
- Oct 15, 2024Dividend: 0.55
- Jan 15, 2025Dividend: 0.59
- Apr 15, 2025Dividend: 0.59
- Jul 15, 2025Dividend: 0.59
- Oct 15, 2025Dividend: 0.59
- Oct 15, 2025Earnings: 1.3; estimate 1.3; surprise 0%
- Jan 15, 2026Dividend: 0.63
- Jan 22, 2026Earnings: 1.5; estimate 1.5; surprise 0%
- Apr 15, 2026Dividend: 0.63
- Apr 16, 2026Earnings: 1.15; estimate 1.14; surprise 0.88%
- Jul 15, 2026Dividend: 0.63
- Jul 16, 2026Earnings: 1.31; estimate 1.28; surprise 2.34%
- Oct 15, 2026Dividend: 0.63
- Oct 21, 2026Earnings: 1.42; estimate 1.42; surprise 0%
- Oct 22, 2026Rating: JP Morgan · Overweight → Overweight
- Oct 22, 2026Rating: Wells Fargo · Overweight → Overweight
- Oct 22, 2026Rating: RBC Capital · Outperform → Outperform
- Oct 22, 2026Rating: Citigroup · Buy → Buy
- Oct 23, 2026Rating: Wells Fargo · Overweight → Overweight
- Oct 27, 2026Downgrade: Argus Research · Buy → Hold
Signals (85)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 26, 2026 | 1 week ago |
| SMA: Bullish | Oct 5, 2026 | 4 weeks ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| SMA: Bearish | Sep 7, 2026 | 1 month ago |
| SMA: Bullish | Jul 20, 2026 | 3 months ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 22, 2026 | 4 months ago |
| RSI: Oversold | Mar 30, 2026 | 7 months ago |
| RSI: Oversold | Jan 19, 2026 | 9 months ago |
| SMA: Bearish | Oct 13, 2025 | 1 year ago |
| SMA: Bearish | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Aug 4, 2025 | 1 year ago |
| SMA: Bullish | Aug 4, 2025 | 1 year ago |
| SMA: Bearish | Jul 14, 2025 | 1 year ago |
| SMA: Bearish | Jul 7, 2025 | 1 year ago |
| MACD: Sell Signal | May 19, 2025 | 1 year ago |
| MACD: Buy Signal | May 12, 2025 | 1 year ago |
| SMA: Bullish | Apr 28, 2025 | 1 year ago |
| SMA: Bearish | Apr 21, 2025 | 1 year ago |
| SMA: Bullish | Apr 14, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 31, 2025 | 1 year ago |
| SMA: Bullish | Mar 24, 2025 | 1 year ago |
| SMA: Bearish | Mar 10, 2025 | 1 year ago |
| RSI: Overbought | Feb 10, 2025 | 1 year ago |
| SMA: Bullish | Jan 20, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 20, 2025 | 1 year ago |
| SMA: Bullish | Jan 13, 2025 | 1 year ago |
| SMA: Bearish | Jan 6, 2025 | 1 year ago |
| MACD: Sell Signal | Dec 9, 2024 | 1 year ago |
| SMA: Bearish | Dec 2, 2024 | 1 year ago |
| SMA: Bullish | Oct 28, 2024 | 2 years ago |
| SMA: Bearish | Oct 21, 2024 | 2 years ago |
| SMA: Bullish | Aug 12, 2024 | 2 years ago |
| SMA: Bearish | Aug 5, 2024 | 2 years ago |
| SMA: Bullish | Jul 29, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 29, 2024 | 2 years ago |
| SMA: Bullish | Jul 22, 2024 | 2 years ago |
| SMA: Bearish | Jun 24, 2024 | 2 years ago |
| SMA: Bullish | Jun 17, 2024 | 2 years ago |
| SMA: Bearish | Jun 10, 2024 | 2 years ago |
| SMA: Bullish | Jun 3, 2024 | 2 years ago |
| SMA: Bearish | Apr 22, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 1, 2024 | 2 years ago |
| SMA: Bearish | Mar 18, 2024 | 2 years ago |
| SMA: Bullish | Nov 27, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 20, 2023 | 2 years ago |
| SMA: Bullish | Nov 13, 2023 | 2 years ago |
| MACD: Sell Signal | Aug 14, 2023 | 3 years ago |
| SMA: Bearish | Aug 7, 2023 | 3 years ago |
| SMA: Bearish | Jul 31, 2023 | 3 years ago |
| SMA: Bullish | Jul 10, 2023 | 3 years ago |
| SMA: Bullish | Jul 10, 2023 | 3 years ago |
| SMA: Bearish | Jul 3, 2023 | 3 years ago |
| SMA: Bearish | Jul 3, 2023 | 3 years ago |
| SMA: Bullish | Jun 19, 2023 | 3 years ago |
| SMA: Bullish | Jun 19, 2023 | 3 years ago |
| MACD: Buy Signal | Jun 19, 2023 | 3 years ago |
| MACD: Sell Signal | Jun 5, 2023 | 3 years ago |
| SMA: Bearish | May 22, 2023 | 3 years ago |
| SMA: Bearish | May 22, 2023 | 3 years ago |
| SMA: Bullish | Apr 17, 2023 | 3 years ago |
| MACD: Buy Signal | Apr 17, 2023 | 3 years ago |
| SMA: Bearish | Apr 10, 2023 | 3 years ago |
| SMA: Bullish | Apr 3, 2023 | 3 years ago |
| SMA: Bullish | Apr 3, 2023 | 3 years ago |
| SMA: Bearish | Feb 20, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 20, 2023 | 3 years ago |
| SMA: Bearish | Feb 6, 2023 | 3 years ago |
| SMA: Bullish | Nov 21, 2022 | 3 years ago |
| SMA: Bullish | Nov 7, 2022 | 3 years ago |
| MACD: Buy Signal | Nov 7, 2022 | 3 years ago |
| MACD: Sell Signal | Sep 26, 2022 | 4 years ago |
| SMA: Bearish | Sep 12, 2022 | 4 years ago |
| SMA: Bullish | Sep 5, 2022 | 4 years ago |
| SMA: Bearish | Aug 22, 2022 | 4 years ago |
| SMA: Bullish | Aug 8, 2022 | 4 years ago |
| MACD: Buy Signal | Jun 27, 2022 | 4 years ago |
| SMA: Bearish | Jun 6, 2022 | 4 years ago |
| SMA: Bullish | May 23, 2022 | 4 years ago |
| SMA: Bearish | Apr 25, 2022 | 4 years ago |
| SMA: Bullish | Apr 18, 2022 | 4 years ago |
| SMA: Bearish | Apr 11, 2022 | 4 years ago |
| SMA: Bullish | Apr 4, 2022 | 4 years ago |
| SMA: Bearish | Jan 10, 2022 | 4 years ago |
Key statistics
- Market cap
- 192.07B
- Enterprise value
- 211.54B
- Trailing P/E
- 40.99
- Forward P/E
- 18.57
- PEG ratio
- 1.52
- Price / sales
- 3.98
- Price / book
- 3.73
- EPS (TTM)
- 2.69
- Beta
- 0.54
- Dividend yield
- 2.37%
- Payout ratio
- 78.71%
- Profit margin
- 9.75%
- Revenue (TTM)
- 48.23B
- Revenue growth
- 14.50%
- Free cash flow
- 0
- Total cash
- 5.60B
- Total debt
- 32.72B
- Return on equity
- 0.00%
- Shares outstanding
- 1.74B
- Short % of float
- 1.12%
- 50-day average
- 104.34
- 200-day average
- 101.69
Analyst view
Consensus: buy
- Target (low)
- 100.00
- Target (mean)
- 118.52
- Target (high)
- 130.00
- Strong buy5
- Buy18
- Hold5
- Sell0
- Strong sell0
Next earnings
Jan 28, 2027
Expected Jan 28, 2027. Consensus EPS estimate 1.64.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 28, 2027 | Dec 30, 2026 | 1.64 | — | — | — |
| Oct 21, 2026 | Sep 30, 2026 | 1.42 | 1.42 | 0.00 | 0.00% |
| Jul 16, 2026 | Jun 30, 2026 | 1.28 | 1.31 | +0.03 | +2.34% |
| Apr 16, 2026 | Mar 31, 2026 | 1.14 | 1.15 | +0.01 | +0.88% |
| Jan 22, 2026 | Dec 31, 2025 | 1.50 | 1.50 | 0.00 | 0.00% |
| Oct 15, 2025 | Sep 30, 2025 | 1.30 | 1.30 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 27, 2026 | Argus Research | down | Buy | Hold |
| Oct 23, 2026 | Wells Fargo | main | Overweight | Overweight |
| Oct 22, 2026 | Citigroup | main | Buy | Buy |
| Oct 22, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 22, 2026 | Wells Fargo | main | Overweight | Overweight |
| Oct 22, 2026 | JP Morgan | main | Overweight | Overweight |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- abbott.com
News
- Abbott Touts Favorable Outcomes In Cardiovascular Device Trials
- Abbott Touts Favorable Outcomes In Cardiovascular Device Trials
- Abbott Announces One-Year Results For Its Amulet 360 Left Atrial Appendage Occluder From The VERITAS Study; Data Show Meaningful Closure Rates Of Left Atrial Appendage And A Low Incidence Of Stroke In People With Atrial Fibrillation Not Caused By A Heart Valve Issue
- Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke
- Reported Sunday, Abbott’s TECTONIC Trial Of Investigational SonicForce Coronary IVL System Meets Primary Safety And Effectiveness Endpoints, With 0.3% 30-Day Target Lesion Failure And 97% Procedural Success In 335 Patient
- Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
- Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
- 2 Stocks That Could Quietly Become Big Winners in the Artificial Intelligence (AI) Revolution
- Abbott Initiates CROWN-MV Pivotal Trial Evaluating Safety And Effectiveness Of Its Investigational Cephea Mitral Valve System For Symptomatic Mitral Valve Disease
- Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
Your note
Sign in to keep a note on ABT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLEN HUBERT L. | Officer | Stock Award(Grant) | Feb 24, 2025 | 200,281 |
| BOUDREAU PHILIP P | Chief Financial Officer | Purchase | Apr 22, 2026 | 0 |
| CONROY KEVIN T | Director | Stock Award(Grant) | Apr 23, 2026 | 133,737 |
| EARNHARDT LISA D | Officer | Stock Award(Grant) | Feb 23, 2026 | 98,984 |
| FORD ROBERT B. | Chief Executive Officer | Sale | Aug 24, 2026 | 522,664 |
| MORELAND MARY K | Officer | Sale | Mar 1, 2026 | 116,136 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.82% | 152,563,476 | 16.82B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.57% | 113,750,994 | 12.54B | Jun 29, 2026 |
| State Street Corporation | 4.68% | 80,926,234 | 8.92B | Jun 29, 2026 |
| Charles Schwab Investment Management, Inc. | 3.45% | 59,674,507 | 6.58B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 2.83% | 49,017,866 | 5.41B | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.27% | 39,219,337 | 4.32B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.20% | 55,297,279 | 6.10B | Jun 29, 2026 |
| SCHWAB STRATEGIC TRUST-Schwab US Dividend Equity ETF | 2.75% | 47,631,745 | 5.25B | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.61% | 45,138,490 | 4.98B | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 23,056,907 | 2.54B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.31% | 22,610,290 | 2.49B | Aug 30, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.24% | 21,408,918 | 2.36B | Sep 29, 2026 |